View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Uncategorized
March 22, 2012

Pozen reports positive data from Phase 3 Studies of PA32540

Pozen has reported the positive top-line results from two pivotal Phase 3 clinical trials of PA32540, indicated for the secondary prevention of cardiovascular disease in patients at risk of aspirin-induced ulcers.

Pozen has reported positive top-line results from two pivotal Phase 3 clinical trials of PA32540, indicated for the secondary prevention of cardiovascular disease in patients at risk of aspirin-induced ulcers.

PA32540 is a coordinated-delivery tablet combining immediate-release omeprazole, a proton pump inhibitor, layered around pH-sensitive aspirin.

The two Phase 3 pivotal trials were randomised double-blind multi-centre studies in which a total of 1,049 subjects at risk of developing aspirin-associated ulcers were randomly assigned to treatment with either PA32540 or 325mg enteric-coated aspirin once daily.

The studies met the primary endpoint, including a considerable reduction in the cumulative incidence of gastric ulcers following administration of PA32540 versus 325mg enteric-coated aspirin over six months.

The trials also met secondary endpoints, including a reduction in gastroduodenal ulceration as well as a reduction in discontinuation due to upper gastrointestinal adverse events in subjects taking PA32540 compared to 325mg enteric-coated aspirin.

Pozen president and chief executive officer John Plachetka said: "This information is essential to progress our PA32540 partnership discussions for the United States, and to allow us to continue to move forward with our preparations for a third quarter NDA submission for this product candidate."

Pozen is a progressive pharmaceutical company that is now creating a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage.

The company has already completed the long-term safety study and the two pivotal studies, targeting a New Drug Application submission for Q3 2012.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena